# This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)

> **NCT03604445** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 37 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BI 905677

## Key facts

- **NCT ID:** NCT03604445
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-08
- **Primary completion:** 2022-07-27
- **Final completion:** 2022-07-27
- **Target enrollment:** 37 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03604445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03604445, "This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03604445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*